24 July 2024
Aptamer Group
plc
("Aptamer", the "Company" or
the "Group")
Posting of Circular and
Notice of General Meeting
Aptamer Group plc (AIM: APTA),
the developer of novel Optimer® binders to enable
innovation in the life sciences industry, announces
further to the announcement made earlier today
relating to its proposed Firm Placing, Conditional Placing and
Subscription to raise approximately £2.83 million
("Announcement"), that it has despatched the Circular and Notice of
General Meeting to Shareholders.
The Directors confirm they are to
convene a General Meeting of the Company at 11:00 a.m. on Tuesday
13 August 2024 at Windmill House, Innovation Way, York, YO10
5BR.
The Circular and Notice of General
Meeting is available on the Company's website
at https://aptamergroup.com/investors/reports-and-presentations/
The results of voting on all
resolutions at the General Meeting will be announced via
a Regulatory News Service and the full results of the
voting will be published on the Company's website, as soon as
practicable after the conclusion of the General Meeting.
Capitalised terms used but not otherwise defined in this
announcement shall have the meanings ascribed to such terms in the
Announcement, unless the context requires
otherwise.
- ENDS -
For further information, please
contact:
|
Aptamer Group plc
Dr Arron Tolley
|
+44 (0) 1904 217 404
|
|
SPARK Advisory Partners Limited - Nominated
Adviser
Andrew Emmott / Adam
Dawes
|
+44 (0) 20 3368 3550
|
|
Turner Pope Investments (TPI) Limited - Broker
James Pope / Andrew
Thacker
|
+44 (0) 20 3657 0050
|
About Aptamer Group plc
Aptamer Group develops
custom affinity binders through its
proprietary Optimer® platform to enable new approaches in
therapeutics, diagnostics, and research applications. The Company
strives to deliver transformational solutions that meet the needs
of life science researchers and developers through the use of its
proprietary Optimer® platform.
Optimer® binders are
oligonucleotide affinity ligands that can function as an antibody
alternative. The global affinity ligand market is currently worth
over $170 billion. Optimer® binders are engineered
to address many of the issues found with alternative affinity
molecules, such as antibodies, and offer new, innovative solutions
to bioprocessing, diagnostic and pharmaceutical
scientists.
Aptamer has successfully delivered
projects for global pharma companies, diagnostic development
companies and research institutes covering a range of targets and
applications with the objective of establishing royalty-bearing
licenses. Through the unique Optimer® technology and
processes, scientists and collaborators can make faster, more
informed decisions that support discovery and development across
the Life Sciences.
